Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Nowotwór pęcherza moczowego lub górnych dróg moczowych (nerka, moczowód) potwierdzony badaniem histologicznym
- •Całkowite chirurgiczne usunięcie nowotworu bez widocznych resztek
- •Stwierdzenie nowotwórowych komórek we krwi (wynik testu ctDNA dodatni)
- •Potwierdzenie brakiem przerzutów w badaniach obrazowych
- •Odpowiednia funkcja szpiku kostnego i narządów wewnętrznych
- •Gotowość do stosowania antykoncepcji przez okres badania i 5 miesięcy po jego zakończeniu
- •Zdolność do zrozumienia i podpisania świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
AdventHealth
Orlando, United States
Washington University School of Medicine
St Louis, United States
Ohio State University
Columbus, United States
Trial contact
William Gillanders, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.